NASDAQ · Biotechnology

CELC (CELC) Stock

$92.49 +5.44% NASDAQ: CELC Healthcare

Valuation

MetricValue
Price$92.49
Market Cap$4.51B
P/E Ratio-91.68
P/B Ratio59.83
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$151.02
52-Week Low$9.51
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-1.64%
ROA-30.24%
ROCE-170.30%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity3.65
Current Ratio10.55

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-28.0M$-39.0M$-66.0M$-113.0M$-172.0M
Net Profit$-30.0M$-40.0M$-64.0M$-112.0M$-177.0M
EPS$-2.28$-2.68$-2.69$-2.83$-3.78
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$86.0M$176.0M$191.0M$245.0M$467.0M
Total Liabilities$17.0M$42.0M$51.0M$130.0M$366.0M
Cash$84.0M$25.0M$31.0M$23.0M$166.0M
Borrowings$15.0M$35.0M$37.0M$98.0M$195.0M

Latest News

Why This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digits Investor's Business Daily · Jul 15, 2026 Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval Reuters · Jul 15, 2026 Celcuity gains FDA approval for closely watched breast cancer drug BioPharma Dive · Jul 15, 2026 Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer MarketBeat · Jul 15, 2026 CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug Stocktwits · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-20.0M$-36.0M$-54.0M$-83.0M$-153.0M
Investing Cash Flow$0$-144.0M$-5.0M$-63.0M$-64.0M
Financing Cash Flow$0$0$50.0M$16.0M$0
Net Cash Flow$73.0M$-60.0M$6.0M$-8.0M$143.0M
Free Cash Flow$-20.0M$-36.0M$-54.0M$-84.0M$-154.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.96
EV / EBITDA-34.34
FCF Yield-2.55%
Quick Ratio10.55
Interest Coverage-10.12
Return 1Y549.61%
Return 3Y759.16%
Return 5Y325.14%

Ownership

Insiders Held10.03%
Institutions Held101.79%
Institutions Float Held113.13%
Institutional HolderSharesReport Date
Baker Bros. Advisors, LP7,915,7922026-03-31
Avoro Capital Advisors LLC3,375,0002026-03-31
Perceptive Advisors Llc3,127,2002026-03-31
RTW Investments LP3,039,6212026-03-31
Blackrock Inc.2,711,5322026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPGAscentage Pharma Group International $20.18 +4.89% -9.87 $1.88B 0.00%
APGE $134.19 +0.06% -16.89 $8.30B 0.00%
CGON $72.17 -1.84% -26.72 $6.37B 0.00%
CNTACentessa Pharmaceuticals plc $40.50 +0.00% -22.75 $6.27B 0.00%
IRON $73.86 -1.01% -9.08 $2.82B 0.00%

About CELC

CELC stock trades at $92.49 with a market capitalization of $4.51B. The stock is valued at a price-to-earnings (P/E) ratio of -91.68, price-to-book of 59.83, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $9.51 and $151.02, and currently trades 38.8% below its 52-week high.

On profitability, CELC generates a return on equity (ROE) of -1.64%, return on capital employed of -170.30%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides